newsfilter
← Earnings
Earnings Releases·

Annovis Bio — Third Quarter 2026 Earnings Summary

Annovis Bio, Inc. reported third-quarter 2026 financial results showing cash and cash equivalents of $2.8 million and a net loss of $9.5 million. The company raised $21.0 million in gross proceeds through an underwritten public offering to fund operations through the March 2027 data readout for its Phase 3 DUET-AD Alzheimer's study. Clinical progress includes full enrollment of 862 patients in the DUET-AD trial and 326 patients in the Parkinson's open-label extension study. Upcoming milestones include the last patient visit for the 6-month treatment period on December 31, 2026, and a planned database lock on February 8, 2027.

Company
ANNOVIS BIO INC
Sector
Healthcare
Industry
Biotechnology